In today's era of targeted therapy and immunotherapy, integrating molecular biomarkers of lung cancer such as driver gene mutations, PD‐L1 expression levels, etc., with TNM staging can significantly enhance patient management and outcomes. Here, CD274 is linked to lung cancer.